NeurologyLive | Direct Access to Expert Insight in Neurology

Clinical Focus

Video Series

Publications

Current Issue

Genetic Targets Invigorate Research for Duchenne Muscular Dystrophy

COMT Inhibitors Assist in Control of Parkinson Disease Motor Symptoms

Reldesemtiv Displays Promise Over Predecessor for ALS, Currently in Phase 2b Trial

Advances Answer Some Questions in Excessive Sleepiness, But Raise New Ones

Neuromodulation and Stimulation Devices Offer Additional Options to Patients With Headache Disorders

Drawing on Blood for Biomarkers of Alzheimer Disease

Findings from Jessica Mandrioli, MD

Study results have suggested that no difference in outcomes of function, survival, fatigue, or quality of life are seen between those undergoing intensive or standard exercise regimens.

Marjan Gharagozloo, PhD: Preventing CNS Inflammation and EAE Onset

Gharagozloo spoke about the early phase model of MS she and her colleagues developed to explore the use of Nlrx1, a mitochondria-located innate immune sensor, in CNS inflammation.

Assessments of Alzheimer Agent Aducanumab Discontinued

Eisai and Biogen have announced that the phase 3 ENGAGE and EMERGE trials, in addition to the PRIME phase 1b and EVOLVE phase 2 studies, of the monoclonal antibody, will be discontinued.

Solriamfetol Wins FDA Approval for Excessive Daytime Sleepiness in Narcolepsy, Obstructive Sleep Apnea

The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in OSA in once-daily 37.5 mg, 75 mg, and 150 mg doses.

Ubrogepant Builds Excitement for Additional Acute Migraine Options

The migraine specialist spoke to the CGRP receptor antagonist’s potential impact on patients with migraine who have been lacking a novel acute treatment for some time.

Next Steps in Research in MS

Tanuja Chitnis, MD: Nfl Levels In Long-Term MS Outcomes

Measuring Outcomes in MS